Market Cap
US$103.7m
Last Updated
2020/09/24 05:53 UTC
Data Sources
Company Financials +
Executive Summary
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Outstanding track record with excellent balance sheet.
Share Price & News
How has Pro-Dex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PDEX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-8.8%
PDEX
-2.0%
US Medical Equipment
-1.9%
US Market
1 Year Return
79.0%
PDEX
14.7%
US Medical Equipment
13.1%
US Market
Return vs Industry: PDEX exceeded the US Medical Equipment industry which returned 14.6% over the past year.
Return vs Market: PDEX exceeded the US Market which returned 12.7% over the past year.
Shareholder returns
| PDEX | Industry | Market | |
|---|---|---|---|
| 7 Day | -8.8% | -2.0% | -1.9% |
| 30 Day | 27.9% | 0.2% | -2.9% |
| 90 Day | 50.5% | 13.1% | 8.2% |
| 1 Year | 79.0%79.0% | 15.7%14.7% | 15.7%13.1% |
| 3 Year | 275.1%275.1% | 71.6%67.2% | 38.4%29.1% |
| 5 Year | 1,016.1%1,016.1% | 145.9%127.4% | 89.3%68.0% |
Price Volatility Vs. Market
How volatile is Pro-Dex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Earnings Not Telling The Story For Pro-Dex, Inc. (NASDAQ:PDEX) After Shares Rise 42%2 days ago | Simply Wall St
Do Institutions Own Pro-Dex, Inc. (NASDAQ:PDEX) Shares?2 weeks ago | Simply Wall St
With EPS Growth And More, Pro-Dex (NASDAQ:PDEX) Is InterestingValuation
Is Pro-Dex undervalued compared to its fair value and its price relative to the market?
3.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PDEX ($27.3) is trading below our estimate of fair value ($28.06)
Significantly Below Fair Value: PDEX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PDEX is good value based on its PE Ratio (17.5x) compared to the US Medical Equipment industry average (48.3x).
PE vs Market: PDEX is good value based on its PE Ratio (17.5x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: PDEX is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: PDEX is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Pro-Dex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
5.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDEX's forecast earnings growth (5.4% per year) is above the savings rate (2.2%).
Earnings vs Market: PDEX's earnings (5.4% per year) are forecast to grow slower than the US market (23.1% per year).
High Growth Earnings: PDEX's earnings are forecast to grow, but not significantly.
Revenue vs Market: PDEX's revenue (7% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: PDEX's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PDEX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Pro-Dex performed over the past 5 years?
29.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PDEX has high quality earnings.
Growing Profit Margin: PDEX's current net profit margins (17.5%) are higher than last year (15.3%).
Past Earnings Growth Analysis
Earnings Trend: PDEX has become profitable over the past 5 years, growing earnings by 29.8% per year.
Accelerating Growth: PDEX's earnings growth over the past year (47.4%) exceeds its 5-year average (29.8% per year).
Earnings vs Industry: PDEX earnings growth over the past year (47.4%) exceeded the Medical Equipment industry -0.2%.
Return on Equity
High ROE: PDEX's Return on Equity (32.1%) is considered high.
Next Steps
Financial Health
How is Pro-Dex's financial position?
Financial Position Analysis
Short Term Liabilities: PDEX's short term assets ($22.7M) exceed its short term liabilities ($5.2M).
Long Term Liabilities: PDEX's short term assets ($22.7M) exceed its long term liabilities ($6.8M).
Debt to Equity History and Analysis
Debt Level: PDEX's debt to equity ratio (20.6%) is considered satisfactory.
Reducing Debt: PDEX's debt to equity ratio has increased from 1.1% to 20.6% over the past 5 years.
Debt Coverage: PDEX's debt is well covered by operating cash flow (125.7%).
Interest Coverage: PDEX's interest payments on its debt are well covered by EBIT (50.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Pro-Dex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PDEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PDEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PDEX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PDEX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PDEX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.7yrs
Average board tenure
CEO
Rick Van Kirk (59 yo)
5.67yrs
Tenure
US$454,757
Compensation
Mr. Richard Lee Van Kirk, Jr., also known as Rick, has been the Chief Executive Officer and President of Pro-Dex Inc., since January 12, 2015 and has been its Chief Operating Officer since April 23, 2013. ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD454.76K) is about average for companies of similar size in the US market ($USD601.89K).
Compensation vs Earnings: Rick's compensation has increased by more than 20% in the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 5.67yrs | US$454.76k | 1.54% $ 1.6m | |
| Independent Director | 7.67yrs | US$18.00k | no data | |
| Independent Director | 7.67yrs | US$25.00k | 0.021% $ 21.6k | |
| Independent Chairman of the Board | no data | US$18.00k | 2.49% $ 2.6m | |
| Independent Director | 7.67yrs | US$18.00k | 0.16% $ 167.5k | |
| Director | 0.75yr | no data | 0.18% $ 183.6k |
7.7yrs
Average Tenure
57yo
Average Age
Experienced Board: PDEX's board of directors are considered experienced (7.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PDEX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Pro-Dex, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Pro-Dex, Inc.
- Ticker: PDEX
- Exchange: NasdaqCM
- Founded: 1978
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$103.671m
- Shares outstanding: 3.84m
- Website: https://www.pro-dex.com
Number of Employees
Location
- Pro-Dex, Inc.
- 2361 McGaw Avenue
- Irvine
- California
- 92614
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PDEX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Aug 1986 |
| PDXN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 1986 |
Biography
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/24 05:53 |
| End of Day Share Price | 2020/09/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.